Fusion albumin nanoparticle and application thereof

Patent metadata

Field	Value
Publication number	US-12258384-B2
Application number	US-202117532182-A
Country	US
Kind code	B2
Filing date	Nov 22, 2021
Priority date	Jun 18, 2019
Publication date	Mar 25, 2025
Grant date	Mar 25, 2025

Abstract

The disclosure discloses a fusion albumin nanoparticle and application thereof, and belongs to the technical field of biomedicine. In the disclosure, fusion albumin is expressed by using a genetic engineering technology, and the fusion albumin nanoparticle is formed by performing self-assembly and drug loading on the fusion albumin in a neutral aqueous solution. The fusion albumin studied in the disclosure has targetability, pH and enzyme-sensitive functional groups, the nanoparticle prepared by using the fusion albumin has the functions of targetability and controlled drug release, and a method for preparing the fusion albumin nanoparticle is simple and easy to implement and has great application potential.

First claim

What is claimed is:

1. A fusion protein, wherein the amino acid sequence of the fusion protein is as set forth in SEQ ID NO: 1.

2. A microbial cell, expressing the fusion protein according to claim 1 .

3. The microbial cell according to claim 2 , comprising a bacterial cell or a fungal cell.

4. The microbial cell according to claim 3 , wherein the cell is a yeast cell, comprising Pichia pastoris and Saccharomyces cerevisiae.

5. The microbial cell according to claim 4 , wherein the yeast is Pichia pastoris SMD1168H.

6. The microbial cell according to claim 4 , wherein the yeast is Pichia pastoris SMD1168H, which expresses the fusion albumin as set forth in SEQ ID NO: 1 with pPICZαA as an expression vector.

7. The microbial cell according to claim 4 , wherein the gene encoding the fusion protein according to claim 1 is fused into a genome.

8. A controlled release type pharmaceutical composition, wherein the fusion albumin according to claim 1 is used as a carrier for drug loading.

9. The pharmaceutical composition according to claim 8 , wherein a drug or siRNA is loaded by using a pH response self-assembly technology, and the drug comprises paclitaxel, docetaxel and adriamycin.

10. The pharmaceutical composition according to claim 8 , wherein the pharmaceutical composition is obtained by mixing the fusion albumin and the drug in a ratio of 1:2-10 at a pH of 5-6 and then performing self-assembly at a pH adjusted to 7-8.

11. The pharmaceutical composition according to claim 8 , wherein the drug is used to prevent or treat at least one disease of liver cancer, gastric cancer, lung cancer, breast cancer or cervical cancer.

12. The pharmaceutical composition according to claim 8 , wherein the drug is a tumor cell inhibitor.

13. The pharmaceutical composition according to claim 8 , wherein a tumor cell comprises HepG2, MGC-803, A549, MCF-7 or HeLa.

Assignees

• Univ Jiangnan

Inventors

• Chen Jinghua
• Zhou Juan
• Wang Mingyu

Classifications

• A61K38/00

  Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) · CPC title

• A61K31/704

  attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)} · CPC title

• A61K31/337 Primary

  having four-membered rings, e.g. taxol · CPC title

• A61K9/1658

  Proteins, e.g. albumin, gelatin · CPC title

• A61P35/00

  Antineoplastic agents · CPC title